Krzysztof Jamroziak

List of Publications by Year
in descending order

199	3,020	201385	223531
papers	citations	27 h-index	46 g-index

215	215	215	4146
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A polygenic risk score for multiple myeloma risk prediction. European Journal of Human Genetics, 2022, 30, 474-479.	1.4	5
2	Outcome of SARS-CoV-2-Infected Polish Patients with Chronic Lymphocytic Leukemia. Cancers, 2022, 14, 558.	1.7	6
3	Comparison of Numerical Simulation Techniques of Ballistic Ceramics under Projectile Impact Conditions. Materials, 2022, 15, 18.	1.3	15
4	Structure Formation in Antifriction Composites with a Nickel Matrix and Its Effect on Properties. Materials, 2022, 15, 3404.	1.3	2
5	Finite element modeling of ballistic inserts containing aramid fabrics under projectile impact conditions â€“ Comparison of methods. Composite Structures, 2022, 294, 115752.	3.1	16
6	Tracking Clonal Evolution of Multiple Myeloma Using Targeted Next-Generation DNA Sequencing. Biomedicines, 2022, 10, 1674.	1.4	3
7	Polygenic and multifactorial scores for pancreatic ductal adenocarcinoma risk prediction. Journal of Medical Genetics, 2021, 58, 369-377.	1.5	31
8	Common gene variants within 3â€²â€untranslated regions as modulators of multiple myeloma risk and survival. International Journal of Cancer, 2021, 148, 1887-1894.	2.3	3
9	Predictive significance of selected gene mutations in relapsed and refractory chronic lymphocytic leukemia patients treated with ibrutinib. European Journal of Haematology, 2021, 106, 320-326.	1.1	2
10	Analysis using the finite element method of a novel modular system of additively manufactured osteofixation plates for mandibular fractures - A preclinical study. Biomedical Signal Processing and Control, 2021, 65, 102342.	3.5	6
11	Friction Films and Their Influence on the Antifriction Properties of New High-Temperature Nickel Composites. Lecture Notes in Mechanical Engineering, 2021, , 601-611.	0.3	0
12	Ballistic Impact Resistance of Bulletproof Vest Inserts Containing Printed Titanium Structures. Metals, 2021, 11, 225.	1.0	22
13	Differential Function of a Novel Population of the CD19+CD24hiCD38hi Bregs in Psoriasis and Multiple Myeloma. Cells, 2021, 10, 411.	1.8	7
14	Genomeâ€wide scan of long noncoding <scp>RNA</scp> single nucleotide polymorphism<scp>s</scp> and pancreatic cancer susceptibility. International Journal of Cancer, 2021, 148, 2779-2788.	2.3	23
15	Expression quantitative trait loci of genes predicting outcome are associated with survival of multiple myeloma patients. International Journal of Cancer, 2021, 149, 327-336.	2.3	3
16	Genetically determined telomere length and multiple myeloma risk and outcome. Blood Cancer Journal, 2021, 11, 74.	2.8	10
17	Prompt Determination of the Mechanical Properties of Industrial Polypropylene Sandwich Pipes. Materials, 2021, 14, 2128.	1.3	0
18	Intestinal amyloidosis: Clinical manifestations and diagnostic challenge. Advances in Clinical and Experimental Medicine, 2021, 30, 563-570.	0.6	13

#	Article	IF	Citations
19	Vemurafenib and Rituximab in Patients with Hairy Cell Leukemia Previously Treated with Moxetumomab Pasudotox. Journal of Clinical Medicine, 2021, 10, 2800.	1.0	13
20	Associations between pancreatic expression quantitative traits and risk of pancreatic ductal adenocarcinoma. Carcinogenesis, 2021, 42, 1037-1045.	1.3	14
21	Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. New England Journal of Medicine, 2021, 385, 46-58.	13.9	268
22	Clonal Evolution of Multiple Myelomaâ€"Clinical and Diagnostic Implications. Diagnostics, 2021, 11, 1534.	1.3	4
23	Association of Genetic Variants Affecting microRNAs and Pancreatic Cancer Risk. Frontiers in Genetics, 2021, 12, 693933.	1.1	10
24	Genetic Polymorphisms Involved in Mitochondrial Metabolism and Pancreatic Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 2342-2345.	1.1	4
25	Harmonization of Flow Cytometric Minimal Residual Disease Assessment in Multiple Myeloma in Centers of Polish Myeloma Consortium. Diagnostics, 2021, 11, 1872.	1.3	3
26	Identification of Recessively Inherited Genetic Variants Potentially Linked to Pancreatic Cancer Risk. Frontiers in Oncology, 2021, 11, 771312.	1.3	8
27	Cereblon (CRBN) gene polymorphisms predict clinical response and progression-free survival in relapsed/refractory multiple myeloma patients treated with lenalidomide: a pharmacogenetic study from the IMMEnSE consortium. Leukemia and Lymphoma, 2020, 61, 699-706.	0.6	3
28	Numerical and Experimental Studies of the ÅK Type Shaped Charge. Applied Sciences (Switzerland), 2020, 10, 6742.	1.3	14
29	Long-term Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of the Polish Adult Leukemia Study Group Observational Study. Anticancer Research, 2020, 40, 4059-4066.	0.5	8
30	Efficacy of high-dose corticosteroid-based treatment for chronic lymphocytic leukemia patients with p53 abnormalities in the era of B-cell receptor inhibitors. Advances in Medical Sciences, 2020, 65, 371-377.	0.9	2
31	X-ray Computed Tomography for the Development of Ballistic Composite. Materials, 2020, 13, 5566.	1.3	11
32	Allogeneic hematopoietic cell transplantation for multiple myeloma: A retrospective analysis of the Polish Myeloma Group. Advances in Medical Sciences, 2020, 65, 429-436.	0.9	2
33	Association between the CEBPA and c-MYC genes expression levels and acute myeloid leukemia pathogenesis and development. Medical Oncology, 2020, 37, 109.	1.2	4
34	Friction Mechanism Features of the Nickel-Based Composite Antifriction Materials at High Temperatures. Coatings, 2020, 10, 454.	1.2	14
35	Associations of ficolins and mannose-binding lectin with acute myeloid leukaemia in adults. Scientific Reports, 2020, 10, 10561.	1.6	15
36	A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma. American Journal of Hematology, 2020, 95, 503-509.	2.0	11

#	Article	IF	Citations
37	Assessment of the Impact Resistance of a Composite Material with EN AW-7075 Matrix Reinforced with Î±-Al2O3 Particles Using a 7.62 Ã— 39 mm Projectile. Materials, 2020, 13, 769.	1.3	16
38	Associations of Ficolins With Hematological Malignancies in Patients Receiving High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantations. Frontiers in Immunology, 2020, 10, 3097.	2.2	14
39	Genomeâ€wide association study identifies an early onset pancreatic cancer risk locus. International Journal of Cancer, 2020, 147, 2065-2074.	2.3	20
40	Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients. Leukemia and Lymphoma, 2020, 61, 1885-1893.	0.6	3
41	The impact of cytogenetic evolution and acquisition of del(17p) on the prognosis of multiple myeloma patients. Polish Archives of Internal Medicine, 2020, 130, 483-491.	0.3	3
42	PowikÅ‚adania autologicznego przeszczepienia krwiotwÃ³rczych komÃ³rek macierzystych u pacjentki z ukÅ‚adowÄ… amyloidozÄ… AL. Hematologia, 2020, 11, 50-57.	0.0	1
43	Autologous stem cell transplantation in the treatment of multiple myeloma patients with 17p deletion. Polish Archives of Internal Medicine, 2020, 130, 106-111.	0.3	1
44	Ballistic Head Protection in the Light of Injury Criteria in the Case of the Wz.93 Combat Helmet. Applied Sciences (Switzerland), 2019, 9, 2702.	1.3	18
45	Experimental and metallographic analysis of the energy-absorbing shield subjected to the EFP impact. AIP Conference Proceedings, 2019, , .	0.3	3
46	Expression level of CEBPA gene in acute lymphoblastic leukemia individuals. Scientific Reports, 2019, 9, 15640.	1.6	3
47	Experimental analysis of puncture resistance of aramid laminates on styrene-butadiene-styrene and epoxy resin matrix for ballistic applications. Archives of Civil and Mechanical Engineering, 2019, 19, 1327-1337.	1.9	13
48	Efficacy of daratumumab monotherapy in real-world heavily pretreated patients with relapsed or refractory multiple myeloma. Advances in Medical Sciences, 2019, 64, 349-355.	0.9	16
49	Numerical Analysis of the Dynamic Impact of a Gun Barrel During Firing. Advances in Intelligent Systems and Computing, 2019, , 162-174.	0.5	2
50	Hodgkin lymphoma transformation of chronic lymphocytic leukemiaâ€"A real life data from the Polish Lymphoma Research Group. Hematological Oncology, 2019, 37, 383-391.	0.8	3
51	Concept of a gun barrel based on the layer composite reinforced with continuous filament. AIP Conference Proceedings, 2019, , .	0.3	2
52	Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma. Leukemia, 2019, 33, 2324-2330.	3.3	33
53	Immunochemotherapy for Richter syndrome: current insights . ImmunoTargets and Therapy, 2019, Volume 8, 1-14.	2.7	11
54	Insights on Multiple Myeloma Treatment Strategies. HemaSphere, 2019, 3, e163.	1.2	33

#	Article	IF	Citations
55	High-dimensional Clonal Heterogeneity and Immune Landscape in Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e28-e29.	0.2	0
56	Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia. Cancers, 2019, 11, 1834.	1.7	32
57	Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMEnSE study. Leukemia and Lymphoma, 2019, 60, 1803-1811.	0.6	11
58	Genetic determinants of telomere length and risk of pancreatic cancer: A PANDoRA study. International Journal of Cancer, 2019, 144, 1275-1283.	2.3	36
59	Structure and Properties of the New Antifriction Composite Materials for High-Temperature Friction Units. Lecture Notes in Mechanical Engineering, 2019, , 628-637.	0.3	7
60	Ibrutinib discontinuation in patients with relapsed or refractory chronic lymphocytic leukemia treated in acompassionate use program: A report from the Polish Adult Leukemia Study Group (PALG). Advances in Clinical and Experimental Medicine, 2019, 28, 1051-1057.	0.6	7
61	Qualitative Evaluation of Modeling the Aramid Fabric Elementary Cell in the Piercing Process with a 9Âmm Full Metal Jacket Projectile. Lecture Notes in Mechanical Engineering, 2019, , 581-590.	0.3	0
62	Analysis of heat exchange in the powertrain of a road vehicle with a retarder. Eksploatacja I Niezawodnosc, 2019, 21, 577-584.	1.1	5
63	Ibrutinib Therapy for Chronic Lymphocytic Leukemia Complicated with Secondary Serous Adenocarcinoma of the Peritoneum. UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi, 2019, 29, 186-189.	0.1	0
64	Wyzwania wczesnej diagnostyki szpiczaka plazmocytowego â€“ algorytm diagnostyczny. Acta Haematologica Polonica, 2019, 50, 121-129.	0.1	0
65	Rola brentuksymabu vedotin w leczeniu chorych na opornego/nawrotowego chÅ‚oniaka Hodgkina na przykÅ‚adzie dwÃ³ch opisÃ³w przypadkÃ³w. Hematologia, 2019, 10, 7-16.	0.0	0
66	Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. Nature Communications, 2018, 9, 556.	5.8	188
67	Hodgkin's variant of Richter's transformation during ibrutinib therapy in a series of <scp>CLL</scp> patients; the Polish Adult Leukemia Group report (<scp>PALG</scp>). European Journal of Haematology, 2018, 100, 389-391.	1.1	7
68	Common genetic variants associated with pancreatic adenocarcinoma may also modify risk of pancreatic neuroendocrine neoplasms. Carcinogenesis, 2018, 39, 360-367.	1.3	16
69	Improved manufacturing performance of a new antifriction composite parts based on copper. Engineering Failure Analysis, 2018, 91, 225-233.	1.8	16
70	The analysis of structure of the repaired freight wagon. AIP Conference Proceedings, 2018, , .	0.3	3
71	The Role of Complement Activating Collectins and Associated Serine Proteases in Patients With Hematological Malignancies, Receiving High-Dose Chemotherapy, and Autologous Hematopoietic Stem Cell Transplantations (Auto-HSCT). Frontiers in Immunology, 2018, 9, 2153.	2.2	15
72	Analysis of ballistic resistance of composites based on EN AC-44200 aluminum alloy reinforced with Al2O3 particles. Composite Structures, 2018, 201, 834-844.	3.1	21

#	Article	IF	Citations
73	Inherited variation in the xenobiotic transporter pathway and survival of multiple myeloma patients. British Journal of Haematology, 2018, 183, 375-384.	1.2	11
74	Comorbidity Burden and Use of Concomitant Medications at CML Diagnosis: A Retrospective Analysis of 527 Patients From the Polish Adult Leukemia Group Registry. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, e283-e285.	0.2	5
75	Metallographic analysis of piercing armor plate by explosively formed projectiles. Archives of Civil and Mechanical Engineering, 2018, 18, 1686-1697.	1.9	10
76	The Prognostic Impact of t(14;16) in Multiple Myeloma: A Multicenter Retrospective Study of 213 Patients. Is It Time to Revise the Revised ISS?. Blood, 2018, 132, 4452-4452.	0.6	3
77	Safe administration of rituximab in patients with chronic lymphocytic leukemia and a history of obinutuzumabâ€'associated anaphylaxis. Polish Archives of Internal Medicine, 2018, 128, 494-495.	0.3	3
78	Comparable Efficacy of Idelalisib Plus Rituximab and Ibrutinib in Relapsed/refractory Chronic Lymphocytic Leukemia: A Retrospective Case Matched Study of the Polish Adult Leukemia Group (PALG). Anticancer Research, 2018, 38, 3025-3030.	0.5	7
79	Zalecenia Polskiej Grupy Szpiczakowej dotyczÄ...ce rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2018/2019. Acta Haematologica Polonica, 2018, 49, 157-206.	0.1	4
80	Znaczenie minimalnej choroby resztkowej w szpiczaku plazmocytowym â€" Stanowisko Polskiego Konsorcjum Szpiczakowego. Hematologia, 2018, 8, 246-254.	0.0	1
81	Rola daratumumabu w leczeniu chorych na nawrotowego i opornego szpiczaka plazmocytowego. Hematologia, 2018, 8, 255-264.	0.0	0
82	Praktyka kliniczna oceny minimalnej choroby resztkowej u chorych na szpiczaka plazmocytowego w Polsce: badanie ankietowe Polskiego Konsorcjum Szpiczakowego. Hematologia, 2018, 8, 239-245.	0.0	1
83	Diagnostyka i leczenie amyloidozy AL. Hematologia, 2018, 9, 181-195.	0.0	1
84	Znaczenie oceny minimalnej choroby resztkowej w amyloidozie AL. Hematologia, 2018, 9, 196-201.	0.0	0
85	Jak leczymy pacjenta z nowo rozpoznanÄ... amyloidozÄ... Å‚aÅ„cuchÃ³w lekkich poÅ›redniego ryzyka? Rola doksycykliny w terapii amyloidozy z zajÄ™ciem serca. Hematologia, 2018, 9, 245-253.	0.0	0
86	Doksycyklina w terapii amyloidozy ukÅ‚adowej z zajÄ™ciem serca. Hematologia, 2018, 9, 202-207.	0.0	0
87	Zasady klasyfikacji i nazewnictwa amyloidoz. Hematologia, 2018, 9, 167-172.	0.0	1
88	Szczepienia ochronne u dorosÅ‚ych chorych na nowotwory hematologiczne oraz u chorych z aspleniÄ... â€" zalecenia PTHiT i sekcji do spraw zakaÅ¼eÅ„ PALG. Acta Haematologica Polonica, 2018, 49, 93-101.	0.1	5
89	Nowe terapie w leczeniu szpiczaka z wysokim ryzykiem cytogenetycznym. Acta Haematologica Polonica, 2018, 49, 102-111.	0.1	0
90	Identification of a Subsystem Located in The Complex Dynamical Systems Subjected to Random Loads. Journal of Computational and Nonlinear Dynamics, 2017, 12, .	0.7	3

#	Article	IF	Citations
91	The experimental and numerical analysis of the ballistic resistance of polymer composites. Composites Part B: Engineering, 2017, 113, 24-30.	5.9	50
92	Current Treatment of Chronic Lymphocytic Leukemia. Current Treatment Options in Oncology, 2017, 18, 5.	1.3	17
93	Calculations with the Finite Element Method During the Design Ballistic Armour. Lecture Notes in Mechanical Engineering, 2017, , 451-459.	0.3	4
94	Efficacy and toxicity of compassionate ibrutinib use in relapsed/refractory chronic lymphocytic leukemia in Poland: analysis of the Polish Adult Leukemia Group (PALG). Leukemia and Lymphoma, 2017, 58, 2485-2488.	0.6	34
95	Methods of Identification of Definite Degenerated and Nonlinear Dynamic System Using Specially Programmed Nonharmonic Enforce. Journal of Dynamic Systems, Measurement and Control, Transactions of the ASME, 2017, 139, .	0.9	4
96	Zalecenia Polskiej Grupy Szpiczakowej dotyczÄ...ce rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2017. Acta Haematologica Polonica, 2017, 48, 55-103.	0.1	5
97	Iksazomib u chorych z nawrotowym lub opornym na leczenie szpiczakiem plazmocytowym. Acta Haematologica Polonica, 2017, 48, 160-164.	0.1	0
98	Lack of Association for Reported Endocrine Pancreatic Cancer Risk Loci in the PANDoRA Consortium. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 1349-1351.	1.1	5
99	Analiza skutecznoÅ›ci ibrutynibu w podgrupie chorych na przewlekÅ‚Ä... biaÅ‚aczkÄ™ limfocytowÄ... z delecjÄ... 17p: badanie obserwacyjne Polskiej Grupy ds. Leczenia BiaÅ‚aczek u DorosÅ‚ych (PALG). Acta Haematologica Polonica, 2017, 48, 330-337.	0.1	1
100	Analysis of purely harmonic vibrations in non-linear dynamic systems on the example of the non-linear degenerate system. Procedia Engineering, 2017, 199, 522-527.	1.2	1
101	Numerical Modeling of the Microstructure of Ceramic-Metallic Materials. Procedia Engineering, 2017, 199, 1495-1500.	1.2	8
102	Identification of miRSNPs associated with the risk of multiple myeloma. International Journal of Cancer, 2017, 140, 526-534.	2.3	8
103	Experimental and numerical analysis of aramid fiber laminates with DCPD resin matrix subjected to impact tests. MATEC Web of Conferences, 2017, 112, 04013.	0.1	5
104	Rola idelalizybu w leczeniu chorych na przewlekÅ‚Ä... biaÅ‚aczkÄ™ limfocytowÄ.... Hematologia, 2017, 7, 217-230.	0.0	1
105	Rola wenetoklaksu w leczeniu chorych na przewlekÅ‚Ä... biaÅ‚aczkÄ™ limfocytowÄ.... Hematologia, 2017, 8, 20-32	0.0	1
106	Ocena stanu odÅ¼ywienia pacjentÃ³w z nowotworami ukÅ‚adÃ³w krwiotwÃ³rczego i chÅ‚onnego za pomocÄ... skali PG-SGA. Hematologia, 2017, 8, 105-112.	0.0	0
107	Comparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy. Oncotarget, 2016, 7, 56726-56736.	0.8	58
108	Rekomendacje diagnostyczne i terapeutyczne dla przewlekÅ‚ej biaÅ‚aczki limfocytowej w 2016 r â€“ Raport Grupy Roboczej PTHiT i PALG-CLL. Acta Haematologica Polonica, 2016, 47, 169-183.	0.1	1

#	Article	IF	Citations
109	Zalecenia Polskiej Grupy Szpiczakowej dotyczÄ...ce rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2016. Acta Haematologica Polonica, 2016, 47, 39-85.	0.1	10
110	A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: Results from the IMMEnSE consortium and meta-analysis. Oncotarget, 2016, 7, 59029-59048.	0.8	16
111	Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer risk. Oncotarget, 2016, 7, 57011-57020.	0.8	41
112	Comorbidity Burden and Use of Concomitant Medications at CML Diagnosis: A Retrospective Analysis of 470 Patients from the Polish Adult Leukemia Group (PALG) Registry. Blood, 2016, 128, 1909-1909.	0.6	1
113	Substytucja immunoglobulin u chorych na przewlekÅ‚Ä... biaÅ‚aczkÄ™ limfocytowÄ... i szpiczaka plazmocytowego. Acta Haematologica Polonica, 2015, 46, 233-241.	0.1	0
114	<scp>TERT</scp> gene harbors multiple variants associated with pancreatic cancer susceptibility. International Journal of Cancer, 2015, 137, 2175-2183.	2.3	57
115	Chosen Problems of Selection the Basic Chassis for the Special Purpose Body. Solid State Phenomena, 2015, 220-221, 829-832.	0.3	0
116	Analysis of Material Punching Including a Rotational Speed of the Projectile. Solid State Phenomena, 2015, 220-221, 571-576.	0.3	8
117	Real-life comparison of severe vascular events and other non-hematological complications in patients with chronic myeloid leukemia undergoing second-line nilotinib or dasatinib treatment. Leukemia and Lymphoma, 2015, 56, 2309-2314.	0.6	34
118	Cereblon expression predicts clinical response in chronic lymphocytic leukemia treated with a thalidomide/fludarabine regimen. Leukemia and Lymphoma, 2015, 56, 808-810.	0.6	9
119	Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. Nature Communications, 2015, 6, 7539.	5.8	38
120	Zalecenia Polskiej Grupy Szpiczakowej dotyczÄ...ce rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2015. Acta Haematologica Polonica, 2015, 46, 159-211.	0.1	0
121	Type 2 diabetes-related variants influence the risk of developing multiple myeloma: results from the IMMEnSE consortium. Endocrine-Related Cancer, 2015, 22, 545-559.	1.6	11
122	Clinical relevance of vascular endothelial growth factor type A (VEGFA) and VEGF receptor type 2 (VEGFR2) gene polymorphism in chronic lymphocytic leukemia. Blood Cells, Molecules, and Diseases, 2015, 54, 139-143.	0.6	10
123	Richter syndrome in chronic lymphocytic leukemia: updates on biology, clinical features and therapy. Leukemia and Lymphoma, 2015, 56, 1949-1958.	0.6	48
124	Common variation at 12q24.13 (OAS3) influences chronic lymphocytic leukemia risk. Leukemia, 2015, 29, 748-751.	3.3	24
125	Risk of multiple myeloma is associated with polymorphisms within telomerase genes and telomere length. International Journal of Cancer, 2015, 136, E351-8.	2.3	30
126	The Method of Determining Certain Parameters of Energy Absorption in Materials Under Complex Dynamic Excitations. Springer Proceedings in Energy, 2015, , 597-605.	0.2	0

#	Article	IF	Citations
127	PostÄ™py w diagnostyce i leczeniu chorych na szpiczaka plazmocytowego. Hematologia, 2015, 6, 10-18.	0.0	0
128	Etiologia i patogeneza szpiczaka plazmocytowego. Hematologia, 2015, 6, 245-263.	0.0	0
129	The Analysis of Hydrogen Absorption by the Fatigue Crack in Changeable Loaded Structure. Advanced Materials Research, 2014, 1036, 541-546.	0.3	2
130	The Analysis of Energy Consumption of a Ballistic Shields in Simulation of Mobile Cellular Automata. Advanced Materials Research, 2014, 1036, 680-685.	0.3	9
131	Long-term results of the Polish Adult Leukemia Group PALG-CLL2 phase III randomized study comparing cladribine-based combinations in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2014, 55, 606-610.	0.6	5
132	Analysis of Non-Classical Models which Have been Subjected to Percussive Loads Using Equations of Energy and Power. Advanced Materials Research, 2014, 1036, 608-613.	0.3	2
133	Polymorphism of CD44 Influences the Efficacy of CD34+ Cells Mobilization in Patients with Hematological Malignancies. Biology of Blood and Marrow Transplantation, 2014, 20, 986-991.	2.0	25
134	Genetic Variants and Multiple Myeloma Risk: IMMEnSE Validation of the Best Reported Associationsâ€"An Extensive Replication of the Associations from the Candidate Gene Era. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 670-674.	1.1	13
135	Znaczenie bortezomibu w leczeniu szpiczaka plazmocytowego u pacjentÃ³w z ryzykiem cytogenetycznym. Acta Haematologica Polonica, 2014, 45, 247-257.	0.1	0
136	An identification of nonlinear dissipative properties of constructional materials at dynamical impact loads conditions. Meccanica, 2014, 49, 1955-1965.	1.2	14
137	Rekomendacje diagnostyczne i terapeutyczne dla przewlekÅ‚ej biaÅ‚aczki limfocytowej w 2014 r. â€“ raport Grupy Roboczej PTHiT oraz PALG â€“ CLL. Acta Haematologica Polonica, 2014, 45, 221-239.	0.1	3
138	Cereblon (CRBN) Gene Polymorphisms Predict Clinical Response and Progression-Free Survival in Multiple Myeloma Patients Treated with Lenalidomide: A Pharmacogenetic Study of Immense Consortium. Blood, 2014, 124, 3628-3628.	0.6	4
139	Abstract 5078: Genome wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. , 2014, , .		0
140	Type 2 Diabetes-Related Variants Influence on the Risk of Developing Multiple Myeloma: Results from the Immense Consortium. Blood, 2014, 124, 2044-2044.	0.6	0
141	Impact of Drug Transporters ABCB1 and ABCG2 and Regulators of Xenobiotic Transport and Metabolism Pxr and CAR Gene Polymorphisms on Clinical Efficacy of Imatinib in Chronic Myeloid Leukemia (CML). Blood, 2014, 124, 5222-5222.	0.6	0
142	The International Multiple Myeloma Research (IMMEnSE) Consortium: Genetics of Multiple Myeloma Risk and Prognosis. Blood, 2014, 124, 3421-3421.	0.6	0
143	Polymorphisms of the glucocorticoid receptor gene: impact on clinical outcome of multiple myeloma. Comparative Clinical Pathology, 2013, 22, 157-163.	0.3	0
144	Genetic susceptibility to pancreatic cancer and its functional characterisation: The PANcreatic Disease ReseArch (PANDoRA) consortium. Digestive and Liver Disease, 2013, 45, 95-99.	0.4	45

#	Article	IF	Citations
145	Polymorphisms in regulators of xenobiotic transport and metabolism genes PXR and CAR do not affect multiple myeloma risk: a caseâ€“control study in the context of the IMMEnSE consortium. Journal of Human Genetics, 2013, 58, 155-159.	1.1	5
146	Cereblon: molekularny cel lekÃ³w immunomodulujÄ…cych. Acta Haematologica Polonica, 2013, 44, 200-207.	0.1	0
147	CD38 gene polymorphisms and genetic predisposition to multiple myeloma. Acta Haematologica Polonica, 2013, 44, 58-62.	0.1	1
148	Lack of Replication of Seven Pancreatic Cancer Susceptibility Loci Identified in Two Asian Populations. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 320-323.	1.1	20
149	ABO blood groups and pancreatic cancer risk and survival: Results from the PANcreatic Disease ReseArch (PANDoRA) consortium. Oncology Reports, 2013, 29, 1637-1644.	1.2	55
150	Real-Life Comparison Of Severe Vascular Events and Other Non-Hematological Complications In CML Patients Treated With Second Line Nilotinib Or Dasatinib. Blood, 2013, 122, 1491-1491.	0.6	3
151	A Randomized, Multicenter Study (PALG CLL4/ ML 21283) Of Maintenance Treatment With Rituximab Versus Observation After Induction Treatment With Rituximab, Cladribine, and Cyclophosphamide (RCC) Regimen In Patients With Progressive Chronic Lymphocytic Leukemia: Interim Analysis. Blood, 2013, 122, 1640-1640.	0.6	1
152	Polymorphism Of CD44 Influences Efficacy Of CD34+Cells Mobilization In Patients With Hematological Malignancies. Blood, 2013, 122, 3270-3270.	0.6	0
153	High Expression Of Cereblon (CRBN) Is Associated With Achievement Of Complete Response To Thalidomide Plus Fludarabine Regimen In Chronic Lymphocytic Leukemia. Blood, 2013, 122, 4934-4934.	0.6	0
154	Polymorphisms in xenobiotic transporters ABCB1, ABCG2, ABCC2, ABCC1, ABCC3 and multiple myeloma risk: a caseâ€“control study in the context of the International Multiple Myeloma rESEarch (IMMEnSE) consortium. Leukemia, 2012, 26, 1419-1422.	3.3	14
155	Systematic review of purine analog treatment for chronic lymphocytic leukemia: lessons for future trials. Haematologica, 2012, 97, 428-436.	1.7	24
156	Impact of polymorphic variation at 7p15.3, 3p22.1 and 2p23.3 loci on risk of multiple myeloma. British Journal of Haematology, 2012, 158, 805-809.	1.2	19
157	Zalecenia Polskiej Grupy Szpiczakowej dotyczÄ…ce rozpoznawania i leczenia szpiczaka plazmocytowego na rok 2012. Acta Haematologica Polonica, 2012, 43, 7-47.	0.1	5
158	Variants of CD38 gene and lipid metabolism: A link in chronic lymphocytic leukemia?. Leukemia Research, 2012, 36, 1227-1228.	0.4	1
159	Comprehensive investigation of genetic variation in the 8q24 region and multiple myeloma risk in the <scp>IMME</scp>n<scp>SE</scp> consortium. British Journal of Haematology, 2012, 157, 331-338.	1.2	13
160	Poor prognosis of Hodgkin variant of Richter transformation in chronic lymphocytic leukaemia treated with cladribine â€•Response to Jamroziak etÂal. British Journal of Haematology, 2012, 158, 289-289.	1.2	1
161	Poor prognosis of <scp>H</scp>odgkin variant of <scp>R</scp>ichter transformation in chronic lymphocytic leukemia treated with cladribine. British Journal of Haematology, 2012, 158, 286-288.	1.2	20
162	Genetics and molecular epidemiology of multiple myeloma: The rationale for the IMMEnSE consortium (Review). International Journal of Oncology, 2011, 40, 625-38.	1.4	14

#	Article	IF	Citations
163	Common genetic variation at 15q25.2 impacts on chronic lymphocytic leukaemia risk. British Journal of Haematology, 2011, 154, 229-233.	1.2	19
164	Comparison of Cladribine Plus Cyclophosphamide With Fludarabine Plus Cyclophosphamide As First-Line Therapy for Chronic Lymphocytic Leukemia: A Phase III Randomized Study by the Polish Adult Leukemia Group (PALG-CLL3 Study). Journal of Clinical Oncology, 2010, 28, 1863-1869.	0.8	86
165	Clinical Relevance of Vascular Endothelial Growth Factor Type A (VEGFA) and VEGF Receptor Type 2 (VEGFR2) Gene Polymorphism In Chronic Lymphocytic Leukemia. Blood, 2010, 116, 4467-4467.	0.6	0
166	CD38Gene Polymorphisms Contribute to Genetic Susceptibility to B-Cell Chronic Lymphocytic Leukemia: Evidence from Two Case-Control Studies in Polish Caucasians. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 945-953.	1.1	32
167	Activity of cladribine combined with cyclophosphamide in frontline therapy for chronic lymphocytic leukemia with 17p13.1/TP53 deletion. Cancer, 2009, 115, 94-100.	2.0	26
168	ABCB1 gene polymorphisms and haplotype analysis in colorectal cancer. International Journal of Colorectal Disease, 2009, 24, 895-905.	1.0	45
169	Polymorphisms and haplotypes in the multidrug resistance 1 gene (MDR1/ABCB1) and risk of multiple myeloma. Leukemia Research, 2009, 33, 332-335.	0.4	33
170	Current and Emerging Treatments for Chronic Lymphocytic Leukaemia. Drugs, 2009, 69, 2415-2449.	4.9	39
171	Evaluation of circulating endothelial cells as noninvasive marker of angiogenesis in patients with chronic lymphocytic leukemia. Leukemia and Lymphoma, 2009, 50, 62-67.	0.6	20
172	Do polymorphisms in ABC transporter genes influence risk of childhood acute lymphoblastic leukemia?. Leukemia Research, 2008, 32, 1173-1175.	0.4	10
173	Randomized Comparison of Cladribine Plus Cyclophosphamide with Fludarabine Plus Cyclophosphamde in Untreated Patients with Chronic Lymphocytic Leukemia: Report of the Polish Adult Leukemia Group (PALG-CLL3).. Blood, 2008, 112, 2103-2103.	0.6	1
174	Polymorphisms in CD31/PECAM-1 and CD38 Genes Are Associated with Susceptibility to Multiple Myeloma. Blood, 2008, 112, 5113-5113.	0.6	0
175	Genetic polymorphisms in the proximal IL-10 promoter and susceptibility to non-Hodgkin lymphoma. Leukemia and Lymphoma, 2007, 48, 2235-2238.	0.6	21
176	Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial. Blood, 2007, 109, 3672-3675.	0.6	70
177	Human leukocyte antigens HLA DRB1 influence clinical outcome of chronic lymphocytic leukemia. Haematologica, 2007, 92, 710-711.	1.7	12
178	CD38 Gene Polymorphisms Contribute to Genetic Predisposition to B-Cell Chronic Lymphocytic Leukemia.. Blood, 2007, 110, 491-491.	0.6	1
179	Influence of High Expression of p73 and p53 Proteins on Clinical Outcome in Acute Myeloid Leukemia Patients.. Blood, 2007, 110, 4306-4306.	0.6	0
180	Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). Blood, 2006, 108, 473-479.	0.6	119

#	Article	IF	Citations
181	No Influence of 3435C>T ABCB1 (MDR1) Gene Polymorphism on Risk of Adult Acute Myeloid Leukemia and P-glycoprotein Expression in Blast Cells. Therapeutic Drug Monitoring, 2006, 28, 707-711.	1.0	23
182	Cladribine in Weekly Versus Daily Schedule for Untreated Active Hairy Cell Leukemia: Final Report of Polish Adult Leukemia Group (PALG) Prospective, Randomized, Multicenter Trial.. Blood, 2006, 108, 2485-2485.	0.6	6
183	Randomized Comparison of Cladribine Plus Cyclophsophamide with Fludarabine Plus Cyclophosphamide in Progressive Chronic Lymphocytic Leukemia: An Updated Report of Prospective PALG-CLL3 Study.. Blood, 2006, 108, 2826-2826.	0.6	1
184	Pharmacogenetics of Response to Glucocorticosteroids in Adults with Acute Lymphoblastic Leukemia.. Blood, 2006, 108, 2609-2609.	0.6	0
185	MDR1 (ABCB1) gene polymorphism C3435T is associated with P-glycoprotein activity in B-cell chronic lymphocytic leukemia. Pharmacological Reports, 2006, 58, 720-8.	1.5	38
186	Proapoptotic activity of alemtuzumab alone and in combination with rituximab or purine nucleoside analogues in chronic lymphocytic leukemia cells. Leukemia and Lymphoma, 2005, 46, 87-100.	0.6	46
187	Pharmacogenetic Analysis of Polymorphisms in Pharmacological Pathway of Vincristine, Doxorubicine and Dexamethasone (VAD Regimen) To Predict Response in Patients with Multiple Myeloma.. Blood, 2005, 106, 104-104.	0.6	1
188	The VH3-21 Gene Status Correlates with Elevated Î²2-Microglobulin Serum Levels and Shorter Overall Survival of Patients with Chronic Lymphocytic Leukemia.. Blood, 2005, 106, 4988-4988.	0.6	0
189	Inhibition of mTOR Kinase Pathway Selectively Sensitizes Acute Myeloid Leukemia Cells to Cytarabine-Induced Apoptosis.. Blood, 2005, 106, 2474-2474.	0.6	0
190	Multi-drug transporter MDR1 gene polymorphism and prognosis in adult acute lymphoblastic leukemia. Pharmacological Reports, 2005, 57, 882-8.	1.5	16
191	Pharmacogenomics ofMDR1/ABCB1Gene: the Influence on Risk and Clinical Outcome of Haematological Malignancies. Hematology, 2004, 9, 91-105.	0.7	74
192	Richter's Syndrome in the Brain First Manifested as an Ischaemic Stroke. Leukemia and Lymphoma, 2004, 45, 1261-1267.	0.6	13
193	Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. European Journal of Haematology, 2004, 72, 314-321.	1.1	172
194	Rapamycin, Inhibitor of Mtor Kinase, Sensitizes Leukemia Cells to Fludarabine-Induced Apoptosis, but Protects Survival of Normal Lymphocytes.. Blood, 2004, 104, 4497-4497.	0.6	2
195	Analysis of Common Single Nucleotide Polymorphisms in MDR1 Gene in Patients with Multiple Myeloma.. Blood, 2004, 104, 4371-4371.	0.6	0
196	Distribution of allelic variants of functional C3435T polymorphism of drug transporter MDR1 gene in a sample of Polish population. Polish Journal of Pharmacology, 2002, 54, 495-500.	0.3	22
197	Critical to Quality Factors of Engineering Design Process of Armoured Vehicles. Solid State Phenomena, 0, 165, 280-284.	0.3	9
198	Parametric Identification of the Degenerate Model with a Dissipative-Elastic Element Dispersing Impact Energy. Solid State Phenomena, 0, 220-221, 213-217.	0.3	1

#	Article	IF	Citations
199	Ocena profilu korzyÅ›ci i ryzyka leczenia idelalizybem u chorych na przewlekÅ‚Ä… biaÅ‚aczkÄ™ limfocytowÄ… i chÅ‚oniaki nie-Hodgkina. Hematologia, 0, , .	0.0	0